The European Medicines Agency鈥檚 Committee for Medicinal Products for Human Use (CHMP) has recommended seven new drugs for authorisation.
The drugs include 鈥檚 Elrexfio for the treatment of multiple myeloma and 鈥檚 Veozah for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Elrexfio (elranatamab) is a subcutaneously administered bispecific B-cell maturation antigen-directed CD3 T-cell engager. The US Food and Drug Administration (FDA) granted accelerated approval for Elrexfio in August for patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
According to GlobalData, sales for Elrexfio are expected to reach $536m by 2029. One of its competitors in the market is Talvey (talquetamab-tgvs), marketed by Janssen, which was as a fifth-line treatment for relapsed/refractory multiple myeloma in August. Talvey is forecasted to generate $1.9bn in sales by 2029.
GlobalData is the parent company of Pharmaceutical Technology.
Astellas Pharma鈥檚 Veozah is a non-hormonal treatment to reduce moderate to severe VMS associated with menopause. Veozah works by blocking neurokinin B binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neurone, reducing hot flashes and night sweats by restoring balance in the hypothalamus, which controls temperature.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe FDA Veozah in May 2023, and sales are expected to reach $2.5bn by 2029. According to , Q1 sales of Veozah were limited, with JPY6m ($40,000), however, Astellas expects sales to reach JPY49.3bn ($3.3bn) as per its full-year forecast.
Among the are 鈥� Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD), Geurbet鈥檚 Elucirem (gadopiclenol) and Bracco Imaging鈥檚 Vueway (gadopiclenol), both used for MRI diagnostics.
The list also includes Immedica Pharma鈥檚 Loargys (pegzilarginase) for the treatment of hyperargininaemia, and Rezzayo (rezafungin), marketed by Mundipharma for the treatment of invasive candidiasis.
